raav2tyf-grk1-rpgr
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2018 (NCT03316560)
Timeline
Indications
Studied for
Mechanism of action
- X-linked retinitis pigmentosa GTPase regulatorSupplementation
supplementation - RPGR
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06333249 | Phase 2 | Apr 13, 2021 | Beacon Therapeutics |
| NCT03316560 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2018 | Applied Genetic Technologies Corp |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Genetic Technologies Corp | For profit | 1 | 1 | 1 | 2018 |
| Beacon Therapeutics | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1